Document is current

Article History

Received: 26 April 2026

Accepted: 15 May 2026

First Online: 26 May 2026

Declarations

:

: This article does not contain any studies with human or animal subjects performed by any of the authors.

: Disclosures: Sularz: None. Cooper: Consulting fees from Bristol Meyers Squibb, CardiolRx, Moderna, and the Chan Zuckerberg Rare as One Foundation and has equity ownership in Stromal Therapeutics, LLC. Tang: Consultant for Cardiol Therapeutics, Zehna Therapeutics, WhiteSwell, Boston Scientific, CardiaTec Biosciences, Bristol Myers Squibb, Alleviant Medical, Alexion Pharmaceuticals, and Salubris Biotherapeutics, BioCardia, Tenax Therapeutics, and has received an honorarium from Springer Nature and Belvoir Publishing. In addition, Dr. Tang is a Section Editor for the journal Current Treatment Options in Cardiovascular Medicine; thus, this paper was reviewed by the Editor-in-Chief. Kafil: None.